Multi-Compartmental Dissolution Method, an Efficient Tool for the Development of Enhanced Bioavailability Formulations Containing Poorly Soluble Acidic Drugs.
BCS Class IIa
IVIVC
ibuprofen
multi-compartmental dissolution
solubility
supersaturation
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
24 Feb 2023
24 Feb 2023
Historique:
received:
17
01
2023
revised:
10
02
2023
accepted:
22
02
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
The purpose of this study was to investigate the applicability of the Gastrointestinal Simulator (GIS), a multi-compartmental dissolution model, to predict the in vivo performance of Biopharmaceutics Classification System (BCS) Class IIa compounds. As the bioavailability enhancement of poorly soluble drugs requires a thorough understanding of the desired formulation, the appropriate in vitro modelling of the absorption mechanism is essential. Four immediate release ibuprofen 200 mg formulations were tested in the GIS using fasted biorelevant media. In addition to the free acid form, ibuprofen was present as sodium and lysine salts in tablets and as a solution in soft-gelatin capsules. In the case of rapid-dissolving formulations, the dissolution results indicated supersaturation in the gastric compartment, which affected the resulting concentrations in the duodenum and the jejunum as well. In addition, a Level A in vitro-in vivo correlation (IVIVC) model was established using published in vivo data, and then the plasma concentration profiles of each formulation were simulated. The predicted pharmacokinetic parameters were consistent with the statistical output of the published clinical study. In conclusion, the GIS method was found to be superior compared to the traditional USP method. In the future, the method can be useful for formulation technologists to find the optimal technique to enhance the bioavailability of poorly soluble acidic drugs.
Identifiants
pubmed: 36986614
pii: pharmaceutics15030753
doi: 10.3390/pharmaceutics15030753
pmc: PMC10051608
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Pharm Sci. 2017 May 1;102:126-139
pubmed: 28263914
Clin Pharmacol Ther. 1986 Jul;40(1):1-7
pubmed: 3522030
Pharm Res. 1995 Mar;12(3):413-20
pubmed: 7617530
Int J Pharm. 2022 Feb 25;614:121415
pubmed: 34973409
Anal Chim Acta. 2010 Jul 12;673(1):40-6
pubmed: 20630176
Eur J Pharm Sci. 2007 Aug;31(5):249-61
pubmed: 17616376
ADMET DMPK. 2020 Sep 17;8(4):375-390
pubmed: 35300192
Eur J Pharm Sci. 2015 Aug 30;76:203-12
pubmed: 25978875
J Pharm Sci. 2006 Jan;95(1):116-25
pubmed: 16315223
J Food Sci. 2010 Nov-Dec;75(9):E627-35
pubmed: 21535598
J Pharm Sci. 2011 Nov;100(11):4756-65
pubmed: 21681753
Eur J Pharm Sci. 2018 Mar 30;115:258-269
pubmed: 29378253
J Pharm Sci. 2014 Nov;103(11):3416-3422
pubmed: 25251982
J Pharm Sci. 2018 Jan;107(1):307-316
pubmed: 28919384
Adv Drug Deliv Rev. 2007 Jul 30;59(7):603-16
pubmed: 17619064
Pak J Pharm Sci. 2019 Sep;32(5):2065-2073
pubmed: 31813872
Clin J Pain. 2015 May;31(5):444-50
pubmed: 25119511
J Pharm Biomed Anal. 2008 Jan 22;46(2):335-41
pubmed: 18055153
Appl Microbiol Biotechnol. 1999 Dec;53(1):108-14
pubmed: 10645630
Aliment Pharmacol Ther. 1992 Aug;6(4):447-58
pubmed: 1420737
J Pharm Biomed Anal. 2013 Sep;83:279-85
pubmed: 23770783
Drugs R D. 2014 Dec;14(4):283-90
pubmed: 25395311
J Pharm Sci. 2016 Feb;105(2):687-696
pubmed: 26375734
Eur J Pharm Sci. 2014 Jun 16;57:342-66
pubmed: 23988843